All In Biotech

Drug Trial Radar · NCT00685360

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis

Last checked: Nov 19, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 481 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

481

Actual

Start

May 8, 2008

Primary completion

Jun 11, 2010

Study completion Jun 11, 2010

Sponsor

Sponsor type
Industry
First posted
May 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days. In addition to an optimized background regimen (OBR), participants will be randomized to receive: * 100 mg OPC-67683 twice daily (BID) * 200 mg OPC-67683 BID * Placebo BID After 56 days participants will complete their optimized background regimen (OBR).

Conditions

  • Tuberculosis, Pulmonary
  • Tuberculosis, Multidrug Resistant
  • Extensively Drug-Resistant Tuberculosis

Interventions

  • DelamanidDrug

    Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

  • Optimized Background Regimen (OBR)Drug

    Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country. Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.

  • PlaceboDrug

    Placebo tablets matching 50-mg tablets of delamanid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) Using the Mycobacteria Growth Indicator Tube (MGIT) SystemTime frame: From the first dose of study drug up to the end of the Post-treatment Follow-up Period (Up to Day 84)
  2. Tmax 1 and 2: Time to Maximal Peak Concentration (Tmax) for Delamanid Following First and Second Daily DoseTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  3. Cmax 1 and 2: Maximal Peak Concentration (Cmax) for Delamanid Following First and Second Daily DoseTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  4. Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  5. Accumulation Ratio for Cmax (Rac[Cmax]) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  6. Accumulation Ratio for AUC From Time 0 to 24 Hours (Rac[AUC0-24h]) for DelamanidTime frame: Pre-dose, 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  7. Time to Maximal Peak Concentration (Tmax) for Delamanid Metabolite (DM)-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  8. Maximal Peak Concentration (Cmax) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  9. Area Under the Plasma Concentration Curve From 0 to 24 Hours (AUC0-24h) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  10. Accumulation Ratio for Cmax (Rac[Cmax]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  11. Accumulation Ratio for AUC (Rac[AUC]) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose up to Day 56
  12. Elimination Half-life (t1/2) for DM-6704, DM-6705, DM-6706, DM-6717, DM-6718, DM-6720, DM-6721, and DM-6722Time frame: 0 hours (morning pre-dose), 2, 3, 4, 10 (pre-evening dose), 12, 13, 14 and 24 hours post-dose on Day 56

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Texas Health Center at Tyler / Heartland National TB Center / Texas Center for Infectious Disease

    San Antonio, Texas

  • Beijing Chest Hospital

    Beijing, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Abbassia Chest Hospital

    Cairo, Egypt

  • North Estonian Medical Centre Foundation

    Tallinn, Estonia

  • Tartu University Lung Hospital

    Tartu, Estonia

  • Kinki Chuo Chest Hospital

    Osaka, Japan

  • Fukujuji Hospital

    Tokyo, Japan

  • Clinic of Tuberculosis and Lung Diseases

    Riga, Latvia

  • Hospital Nacional Daniel Alcides Carrión

    Carrion, Peru

  • Hospital Nacional Sergio E. Bernales

    Lima, Peru

  • Hospital Nacional Hipolito Unanue

    Unánue, Peru

  • Tropical Disease Foundation

    Manila, Philippines

  • Masan Medical Center

    Changwon, South Korea

  • National Masan Hospital

    Masan, South Korea

  • Younsei University Medical Center (YUMC), Severance Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.